Jieyi Meng

Dr. Jieyi Meng

orcid

Research Focus & Metrics

Representative Publications

View All Publications
10 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CLChao Li
Chao Li
JMJun Meng
Jun Meng
TZTongtong Zhang
Tongtong Zhang
Non-SMC condensin I complex subunit H (NCAPH) plays a regulatory role in various cancers. However, its role in prognosis and immune infiltrates in lung adenocarcinoma (LUAD) remains unclear. This study examined the expression of NCAPH in tumor tissues and its association with immune infiltrates and prognostic roles in LUAD patients. Patients characteristics were obtained from The Cancer Genome Atlas (TCGA). Integrated analysis of TCGA showed that NCAPH was overexpressed across cancers, including LUAD. NCAPH expression was verified by quantitative polymerase chain reaction and western blotting in 20 LUAD matched tissues. High NCAPH expression was significantly related to T, N, M, pathologic stage, primary therapy outcome and smoking status according to the Wilcoxon rank sum test. Cox and Kaplan–Meier analyses showed that the NCAPH-high group was associated with shorter OS. The PFI and DSS in the NCAPH-high group were significantly decreased. Multivariate analysis showed that NCAPH was an independent predictive factor for poor prognosis. Gene set enrichment analysis demonstrated that the G2/M checkpoint, ncRNA metabolic, memory B cells, KRAS, E2F targets and MIER1 process were significantly associated with NCAPH expression. Single-sample Gene Set Enrichment Analysis indicated that NCAPH expression was associated with levels of Th2 and mast cells. The impact of NCAPH on malignant phenotypes was evaluated by MTT, transwell, cell cycle and apoptosis assays in vitro. The malignant phenotype of LUAD cells was inhibited if NCAPH was knocked down. In conclusion, this research indicates that NCAPH could be a potential factor for predicting prognosis and a new biomarker in LUAD.

1 December 2009 in Journal of Endourology
Verified
Journal Article
Closed access
JZJunhua Zheng
Junhua Zheng
YXYun-Fei Xu
Yun-Fei Xu
BPBo Peng
Bo Peng
HZHai-Min Zhang
Hai-Min Zhang
YYYang Yan
Yang Yan
JHJian-Hua Huang
Jian-Hua Huang
Objective: The aim of this study was to evaluate the possibility and clinical efficacy of retroperitoneal laparoscopic partial nephrectomy for T1- and T2-stage renal-cell carcinoma (RCC) of a solitary kidney. Patients and Methods: A total of 56 patients with RCC in a solitary kidney were selected in this study, including 41 men and 15 women with a mean age of 49 years. B-type ultrasonography and CT revealed T1N0M0 tumors in 51 cases and T2N0M0 tumors in the remaining 5 cases; 41 cases were RCC in left kidney, and 15 were RCC in right kidney. Of them, 24 cases had RCC located in the upper pole, 24 in the inferior pole, and 8 in the central region of the kidney. The mean tumor diameter was 3.0 ± 0.8 cm (1.5–5.5 cm). Postoperative pathology report showed 46 cases of T1-stage tumor (T1a: 38; T1b: 8) and 10 cases of T2 stage. Retroperitoneal laparoscopic nephron-sparing surgery was performed. Surgical resection was performed along a resection line 0.5 cm from the tumors. Renal function was determined using emission CT before and after operation. Preoperative three-dimensional CT image reconstruction was performed using multislice spiral CT. Results: All procedures were successfully performed without open conversion and serious complications. The mean warm ischemia time was 24 ± 4.2 minutes (19–50 minutes). The mean operation time was 95 ± 14.5 minutes. The mean blood loss volume was 105 ± 20.4 mL. No postoperative urine leakage occurred. Both serum creatinine and nitrogen levels were normal after operation in all cases. The mean hospital stay was 9 ± 2 days. There was no requirement for hemodialysis. No recurrence, metastasis, and implantation were observed during the 20 ± 4month follow-up periods, with a survival rate of 100%. Conclusions: Laparoscopic partial nephrectomy can be performed safely and effectively in selected patients with tumors in a solitary kidney owing to its minimal invasion, clear dissection, less hemorrhage, and rapid recovery.

17 September 2025 in Aging Cell
Verified
Journal Article
Open access
NJNisi Jiang
Nisi Jiang
JYJiyuan Yin
Jiyuan Yin
NLNoah Lawrence
Noah Lawrence
JMJun Meng
Jun Meng
LMLaurence T. Maeyens
Laurence T. Maeyens
SZShangang Zhao
Shangang Zhao
GLP‐1‐based therapy is highly effective in combating aging‐associated metabolic diseases. However, the metabolic effects of frequent withdrawal from this therapy in aged, obese mice have not been previously studied. In this study, aged obese UM‐HET3 mice were assigned to three groups: Group 1 received no liraglutide treatment (Lira OFF); Group 2 underwent 3 cycles of treatment followed by withdrawal (Lira ON/OFF); and Group 3 remained on continuous treatment (Lira ON). As expected, mice in Group 3 showed reduced body weight and food intake, along with improved metabolic health. In contrast, mice in Group 2 developed hyperleptinemia and visceral fat expansion, leading to impaired metabolic health. Importantly, although these mice regained their fat mass after each treatment cycle, they failed to restore lean mass, an unfavorable shift in body composition that may increase vulnerability to aging‐related sarcopenia. These findings suggest that continuous GLP‐1‐based therapy is necessary to sustain metabolic benefits, while intermittent use may promote age‐associated sarcopenia and metabolic decline.

1 April 2013
Verified
Journal Article
Closed access
BLBing Li
Bing Li
YDYong Du
Yong Du
HYHan Feng Yang
Han Feng Yang
YHYayong Huang
Yayong Huang
JMJun Meng
Jun Meng
DXDongmei Xiao
Dongmei Xiao

14 August 2026 in Biology
Verified
Journal Article
Open access
PDF file
CGCharlise Giang
Charlise Giang
JMJun Meng
Jun Meng
MMMahmoud Mohammad
Mahmoud Mohammad
ZLZhenqi Liu
Zhenqi Liu
XWXinle Wu
Xinle Wu
YZYi Zhu
Yi Zhu
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have revolutionized the management of not only type 2 diabetes but also obesity. However, even with rapid therapeutic advances in GLP-1RAs, questions regarding the fundamental principles of GLP-1-mediated weight loss and the enhanced efficacy of next-generation therapies remain. In this comprehensive review article, we first examine the milestones of GLP-1, from its initial discovery and biological characterization to its successful translation into clinical therapy. Furthermore, this review highlights the latest clinical trial data, specifically HbA1c reduction, weight-loss efficacy, and safety profiles, while exploring current pipelines of major pharmaceutical companies. Additionally, we delineate the mechanistic principles underlying the efficacy of GLP-1 single- and multi-receptor agonists and address challenges in mitigating side effects of GLP-1RAs. Finally, we analyze the rapidly evolving landscape of next-generation, incretin-based combination therapies. With an abundance of GLP-1- related therapies already available or in development, we assess how future GLP-1 multi-receptor agonists can achieve enhanced efficacy and how leveraging weight-loss biology, such as set-point theory, can improve therapeutic outcomes.